Voranigo

Nemluvio

Ohtuvayre

Livdelzi

PiaSky

Xolremdi

Isturisa

Quzyttir

Humulin R U-100

Humalog 75/25

Erbitux

Kimmtrak

Mounjaro

Tafinlar + Mekinist 

Trelegy Ellipta 

Incruse Ellipta 

Advair Diskus

Advair HFA

Arnuity Ellipta

Breo Ellipta

Pluvicto

Adakveo

Piqray

Rydapt

Neulasta

Durysta

Doptelet

Vonjo

Kymriah

Xarelto

Tabrecta

Afinitor

Cerdelga

Imcivree

Zavesca

Xywav 

Rylaze

Zepzelca

Vyxeos

Xyrem

Uptravi

Eligard

Namzaric

Elaprase

Cequa

Tresiba

Zeposia

Balversa

Qutenza

Filspari

Dalvance

Lumigan

Liletta

Combigan

Rectiv

Alphagan P

Thymoglobulin

Apidra

Admelog

Jevtana

Elitek 

Multaq

Soliqua

Rinvoq

Faslodex

Hysingla ER

OxyContin

Filsuvez

Cimzia

Jynarque

Onureg

Ninlaro

Kisunla

Lorbrena

Privigen

Relpax

Restasis

Viberzi

Fetzima

Kevzara

Acthar

Votrient

Twirla

Nextstellis

Retevmo

Phexxi

Lantus

Venclexta

Makena

Portrazza

Taytulla

Zemplar

Increlex

Synthroid

Gamifant

Aveed

Androderm

Annovera

Balcoltra

Supprelin LA

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Entyvio

Report Adverse Event 

Prescribing Information

Submit MSL Request 

Pharmacy List

Coverage Authorization Request

Instructions For Use: Prostate Cancer 

Highmark BCBS Northeastern NY - Medicare Prescription Drug Medication Request Form 

Highmark BCBS Western NY - Specialty Drug Prior Authorization Form 

Highmark BCBS Western NY - Non-Formulary Drug Coverage Prior Authorization Form 

Highmark BCBS Western NY - Medicare Specialty Drug Request Form

Highmark BCBS Western NY - Medicare Prescription Drug Medication Request Form 

Wisconsin - Uniform Prior Authorization Form

Washington - Uniform Prior Authorization Form

Oregon - Uniform Prior Authorization Form 

Colorado - Uniform Prior Authorization Form 

Hawaii - Uniform Prior Authorization Form 

Minnesota - Uniform Prior Authorization Form 

New Hampshire - Uniform Prior Authorization Form 

New Mexico - Uniform Prior Authorization Form 

Texas - Uniform Prior Authorization Form 

Louisiana - Uniform Prior Authorization Form 

Arizona - Uniform Prior Authorization Form 

Indiana - Uniform Prior Authorization Form 

Illinois - Uniform Prior Authorization Form 

<section class="Section" data-sectioncode="34089-3"><a name="ID_9cc34126-3008-4e57-88c5-7daee81e6fae"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug.Xofigo is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8.Each milliliter of solution contains 1,100 kBq radium-223 dichloride (30 microcurie), corresponding to 0.58 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Each vial contains 6 mL of solution (6,600 kBq (178 microcurie) radium-223 dichloride at the reference date). The inactive ingredients are 6.3 mg/mL sodium chloride USP (tonicity agent), 7.2 mg/mL sodium citrate USP (for pH adjustment), 0.2 mg/mL hydrochloric acid USP (for pH adjustment), and water for injection USP.The molecular weight of radium-223 dichloride, 223RaCl2, is 293.9 g/mol.Radium-223 has a half-life of 11.4 days. The specific activity of radium-223 is 1.9 MBq (51.4 microcurie)/ng.The six-stage-decay of radium-223 to stable lead-207 occurs via short-lived daughters, and is accompanied predominantly by alpha emissions. There are also beta and gamma emissions with different energies and emission probabilities. The fraction of energy emitted from radium-223 and its daughters as alpha-particles is 95.3% (energy range of 5 - 7.5 MeV). The fraction emitted as beta-particles is 3.6% (average energies are 0.445 MeV and 0.492 MeV), and the fraction emitted as gamma-radiation is 1.1% (energy range of 0.01 - 1.27 MeV). </section>